41 reports of this reaction
1.3% of all ACETAMINOPHEN AND CODEINE PHOSPHATE reports
#20 most reported adverse reaction
CONFUSIONAL STATE is the #20 most commonly reported adverse reaction for ACETAMINOPHEN AND CODEINE PHOSPHATE, manufactured by Aurolife Pharma, LLC. There are 41 FDA adverse event reports linking ACETAMINOPHEN AND CODEINE PHOSPHATE to CONFUSIONAL STATE. This represents approximately 1.3% of all 3,182 adverse event reports for this drug.
Patients taking ACETAMINOPHEN AND CODEINE PHOSPHATE who experience confusional state should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONFUSIONAL STATE is a less commonly reported adverse event for ACETAMINOPHEN AND CODEINE PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to confusional state, the following adverse reactions have been reported for ACETAMINOPHEN AND CODEINE PHOSPHATE:
The following drugs have also been linked to confusional state in FDA adverse event reports:
CONFUSIONAL STATE has been reported as an adverse event in 41 FDA reports for ACETAMINOPHEN AND CODEINE PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONFUSIONAL STATE accounts for approximately 1.3% of all adverse event reports for ACETAMINOPHEN AND CODEINE PHOSPHATE, making it a notable side effect.
If you experience confusional state while taking ACETAMINOPHEN AND CODEINE PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.